R. Kim

Predictors of clinical outcomes of resected ampullary adenocarcinoma: A single-institution experience

Aleksandr Lazaryan, Sujith Kalmadi, Khaldoun Almhanna et al. · European Journal of Surgical Oncology · 2011 · 28 citations

Surgical Oncology, Resected Ampullary Adenocarcinoma, Single-institution Experience +7

O-20 Phase I/IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer

R. Kim, Iman Imanirad, Estrella M. Carballido et al. · Annals of Oncology · 2020 · 20 citations

Medicine, Refractory Colorectal Cancer, Colorectal Cancer +5

Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC)

R. Kim, Debashis Sarker, Teresa Macarulla et al. · Annals of Oncology · 2017 · 17 citations

Hepatology, Medicine, Pathology +10

A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC)

R. Kim, D. Kim, Olatunji B. Alese et al. · Annals of Oncology · 2018 · 16 citations · Full text

Surgical Oncology, Cancer Management, Pathology +19

Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D

R. Kim, Jorge Chaves, Petr Kavan et al. · Annals of Oncology · 2019 · 11 citations